STOCK TITAN

Dermata Therapeutics tops 1,000 Tome orders since launch

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Dermata Therapeutics, Inc. (DRMA) issued a press release highlighting additional results and photos from a recently completed cosmetic clinical study evaluating Tome Foundational Treatment, which the company describes as a recently launched once-weekly skin renewal treatment.

Filing Explained

Dermata reports over 1,000 orders since the launch of Tome Foundational Treatment, adding a commercial order-count measure to the disclosure.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Orders since launch Over 1,000 orders Tome Foundational Treatment
cosmetic clinical study medical
"results and photos from a recently completed cosmetic clinical study"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many orders has DRMA received for Tome Foundational Treatment?

Dermata reported over 1,000 orders since the treatment’s launch.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001853816 0001853816 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 17, 2026

 

DERMATA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40739   86-3218736
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

3525 Del Mar Heights Rd., #322, San Diego, CA   92130
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 800-2543

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share   DRMA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 

 

 

Item 8.01. Other Events.

 

On November 17, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release highlighting additional results and photos from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company’s recently launched once-weekly skin renewal treatment. The Company has received over 1,000 orders since launch.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  DERMATA THERAPEUTICS, INC.
     
Dated: November 17, 2026 By: /s/ Gerald T. Proehl
  Name:  Gerald T. Proehl
  Title: Chief Executive Officer

 

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading